Susquehanna International Group
PTGX icon

Susquehanna International Group’s Protagonist Therapeutics PTGX Stock Holding History

Susquehanna International Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$738K Sell
7,000
-341,600
-98% -$30.2M ﹤0.01% 8675
2025
Q4 		$30.4M Buy
348,600
+280,100
+409% +$22.9M ﹤0.01% 1806
2025
Q3 		$4.55M Sell
68,500
-53,500
-44% -$3.04M ﹤0.01% 4234
2025
Q2 		$6.74M Sell
122,000
-32,500
-21% -$1.56M ﹤0.01% 3452
2025
Q1 		$7.47M Buy
154,500
+105,500
+215% +$4.42M ﹤0.01% 2934
2024
Q4 		$1.89M Buy
49,000
+25,200
+106% +$1.1M ﹤0.01% 5448
2024
Q3 		$1.07M Buy
23,800
+16,800
+240% +$679K ﹤0.01% 6634
2024
Q2 		$243K Sell
7,000
-17,800
-72% -$521K ﹤0.01% 9931
2024
Q1 		$717K Sell
24,800
-163,600
-87% -$4.45M ﹤0.01% 7645
2023
Q4 		$4.32M Sell
188,400
-8,200
-4% -$143K ﹤0.01% 3951
2023
Q3 		$3.28M Sell
196,600
-197,600
-50% -$3.83M ﹤0.01% 4229
2023
Q2 		$10.9M Sell
394,200
-206,800
-34% -$5.18M ﹤0.01% 2399
2023
Q1 		$13.8M Buy
601,000
+249,200
+71% +$4.19M ﹤0.01% 2081
2022
Q4 		$3.84M Buy
351,800
+142,300
+68% +$1.2M ﹤0.01% 3638
2022
Q3 		$1.77M Buy
209,500
+24,700
+13% +$234K ﹤0.01% 5182
2022
Q2 		$1.46M Buy
184,800
+92,900
+101% +$1.12M ﹤0.01% 5599
2022
Q1 		$2.18M Sell
91,900
-142,700
-61% -$4.02M ﹤0.01% 5288
2021
Q4 		$8.02M Sell
234,600
-173,400
-43% -$5.48M ﹤0.01% 3018
2021
Q3 		$7.23M Buy
408,000
+398,800
+4,335% +$17M ﹤0.01% 3356
2021
Q2 		$413K Sell
9,200
-8,000
-47% -$264K ﹤0.01% 10055
2021
Q1 		$445K Buy
17,200
+6,700
+64% +$170K ﹤0.01% 9750
2020
Q4 		$212K Buy
+10,500
New +$226K ﹤0.01% 9945

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Susquehanna International Group's PTGX Position: Q1 2026 in Review

Susquehanna International Group increased its Protagonist Therapeutics (PTGX) stake by 1,325% in Q1 2026, buying an estimated $13.8M and bringing the position to 167,576 shares worth $17.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2380.

Susquehanna International Group first reported a position in PTGX in Q4 2018 and has held it in 25 quarters since. 318 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Susquehanna International Group held 167,576 shares of Protagonist Therapeutics worth $17.7M as of Q1 2026.
  • Susquehanna International Group bought 155,814 Protagonist Therapeutics shares in Q1 2026, an estimated $13.8M.
  • Protagonist Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2380 holding.
  • Susquehanna International Group first reported a position in Protagonist Therapeutics in Q4 2018 and has held it in 25 quarters since.
  • 318 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.